Novo Holdings participates in USD 100m financing round of Chinese contractor
Novo Holdings and a syndicate of other investors have injected USD 100m into Chinese contract developer Zhenge Biotech, expanding on Novo Holdings's bet on Asia, which began with the establishment of a new division in Singapore back in 2020.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
The Novo Nordisk Foundation's holding company Novo Holdings has once again demonstrated its belief in Asia, this time in the form of an investment in Chinese firm Zhenge Biotech, which is a Contract Development and Manufacturing Organization (CDMO).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings plans to enter China
For subscribers
Set-in-stone criteria will reduce risk for new biotech fund
For subscribers
.jpg&w=384&q=75)
